Finance News

AI Biotech, BioXcel Therapeutics, Files for $69M IPO

3.1 from 11 votes
Tuesday, February 13, 2018

BioXcel, which is using AI to develop treatments for neurological disorders and cancers, filed on Monday with the SEC to raise up to $69 million in an initial public offering.

The Branford, CT-based company was founded in 2017 and plans to list on the Nasdaq under the symbol BTAI. Barclays, UBS Investment Bank and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The article BioXcel Therapeutics, an artificial intelligence biotech, files for a $69 million IPO originally appeared on IPO investment manager Renaissance Capital's web site

About BioXcel Therapeutics
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.

Phone: +1 203 643 8060

Source: BioXcel Therapeutics, Inc.
3.1 from 11 votes
Free Newsletter